Nvidia’s Market Cap Rises Above $3 Trillion As Rally Accelerates
Nvidia’s (NVDA) market capitalization is back above $3 trillion U.S. and ahead of Apple (AAPL) as the company’s share price soars amid a broader stock market rally.Nvidia is now the second largest publicly traded U.S. company by market capitalization, behind only Microsoft (MSFT).The chipmaker hit the $3 trillion U.S. milestone as its stock soared 6% on May 13 to briefly rise above $130 U.S. a share. Nvidia’s market cap now stands at $3.17 trillion U.S. The stock was last above $3 trillion U.S. on Feb. 28 of this year, according to market data. The rally on May 13 built on a 5% gain the day before on news of a U.S.-China trade deal that is likely to ease the sale of Nvidia’s microchips in the Chinese market.Nvidia’s stock is also getting a boost from news that the U.S. company is partnering with Saudi Arabia’s state-backed Humain on a 500-megawatt data centre project. The data center project with Saudi Arabia is expected to require several hundred thousand of Nvidia’s most advanced microchips and processors over the next five years. Nvidia’s stock had been on a downswing in recent months but is now rebounding. The company is scheduled to report its quarterly financial results on May 28, which many analysts say will be a test for the company, its stock, and the market.As the latest rally gathers steam, Nvidia’s stock is down 6% on the year and trading at $129.93 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


